Eikon Therapeutics Announces Lease for East Coast Base of Operations in New York City
HAYWARD, Calif. & NEW YORK--(BUSINESS WIRE)--Eikon Therapeutics Inc., a biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a lease with Alexandria Real Estate Equities, Inc. for its new East Coast base of operations located in the Alexandria Center® for Life Science in New York City.
The 25,000 square foot mixed-use facility will allow Eikon to establish a clinical development arm, expand upon existing research functions, attract top talent on both U.S. coasts, and explore potential collaborations with entities on the East Coast.
Eikon’s Chief Medical Officer, Roy Baynes, MB, BCh, MMed, PhD, will lead the company’s East Coast site operations. “With this state-of-the-art facility, we gain access to the New York metropolitan area’s unmatched pool of talent, including physicians and scientists that have trained at some of the world’s most renowned universities, clinical research institutions, and biopharmaceutical companies,” said Baynes.
“Eikon is proud to join the community of life science companies based in the New York City region, and we are privileged to have Dr. Roy Baynes to lead this expansion,” said Roger M. Perlmutter, MD, PhD, Chairman and CEO of Eikon Therapeutics. “Roy’s deep expertise in clinical development positions us to attract gifted physician-scientists to Eikon’s research enterprise.”
“We are honored to expand our strategic relationship with Eikon,” said John Cunningham, Executive Vice President – Regional Market Director – NYC at Alexandria Real Estate Equities, Inc. “The Alexandria Center will provide Eikon with an inspiring environment from which to recruit and retain top talent as the company advances its groundbreaking platform.”
Eikon recently announced that it is also collaborating with Alexandria to develop the company’s new 285,000 square-foot global headquarters in Millbrae, California.
Eikon Therapeutics was represented in this transaction by Cushman & Wakefield.
About Eikon Therapeutics
Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing with the goal of bringing important new medicines to patients suffering from grievous illness. Scientists at Eikon measure the real-time movement of individual proteins in living cells to develop differentiated therapeutics. Eikon is headquartered in California and can be found online via our website or on Twitter or LinkedIn.